About The Cover
Paclitaxel inhibition of cell migration. A mixed culture of wild-type CHO cells and HAβ3-5 cells was scratched to make a wound and the cells were allowed to migrate for 24 h in the absence or presence of 10 nM paclitaxel. The cells were then stained for α-tubulin (red), HAβ3-tubulin (green), and DNA (blue). See Ganguly et al.
Table of Contents
Editorial Comments
Mycoplasmas and Human prostate cancer: An exciting but cautionary note
| Mycoplasmas and Human prostate cancer: An exciting but cautionary note |
|
https://doi.org/10.18632/oncotarget.282 Shyh-Ching Lo, and Shien Tsai |
| 352-355 |
| Abstract | PDF | HTML | How to cite |
Proteotoxic stress targeted therapy (PSTT)
| Proteotoxic stress targeted therapy (PSTT) |
|
https://doi.org/10.18632/oncotarget.284 Michael Y. Sherman |
| 356-357 |
| Abstract | PDF | HTML | How to cite |
Brief Reports
Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifact
| Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifact |
|
https://doi.org/10.18632/oncotarget.287 Jiawen Yang, Partho Battacharya, Ruchi Singhal, and Eugene S. Kandel |
| 358-362 |
| Abstract | PDF | HTML | How to cite |
|
Research Papers
Netrin-1 overexpression is predictive of ovarian malignancies
| Netrin-1 overexpression is predictive of ovarian malignancies |
|
https://doi.org/10.18632/oncotarget.258 Anastasios D. Papanastasiou, Georgios Pampalakis, Dionyssios Katsaros, and Georgia Sotiropoulou |
| 363-367 |
| Abstract | PDF | HTML | How to cite |
Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration
| Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration |
|
https://doi.org/10.18632/oncotarget.250 Anutosh Ganguly, Hailing Yang, and Fernando Cabral |
| 368-377 |
| Abstract | PDF | HTML | Supplementary Information | How to cite | Podcast | Video Interview |
Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
| Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors |
|
https://doi.org/10.18632/oncotarget.269 Asfar S. Azmi, Sanjeev Banerjee, Shadan Ali, Zhiwei Wang, Bin Bao, Frances WJ Beck, Anthony F. Shields, Philip Philip, Fazlul H. Sarkar, and Ramzi M. Mohammad |
| 378-392 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
| No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis |
|
https://doi.org/10.18632/oncotarget.278 Katharina Bluemlein, Nana-Maria Grüning, René G. Feichtinger, Hans Lehrach, Barbara Kofler, and Markus Ralser |
| 393-400 |
| Abstract | PDF | HTML | How to cite |
Research Perspectives
YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention
| YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention |
|
https://doi.org/10.18632/oncotarget.276 Alastair H. Davies, and Sandra E. Dunn |
| 401-406 |
| Abstract | PDF | HTML | How to cite |
Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity
| Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity |
|
https://doi.org/10.18632/oncotarget.272 Mehdi Mollapour, Shinji Tsutsumi, Yeong Sang Kim, Jane Trepel, and Len Neckers |
| 407-417 |
| Abstract | PDF | HTML | How to cite |
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link
| Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link |
|
https://doi.org/10.18632/oncotarget.277 Simone Fulda |
| 418-421 |
| Abstract | PDF | HTML | How to cite |
c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard
| c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard |
|
https://doi.org/10.18632/oncotarget.279 Karoline Kollmann, Gerwin Heller, and Veronika Sexl |
| 422-427 |
| Abstract | PDF | HTML | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals